Immune-Related Adverse Events Involving Multiple Organ Sites in a Patient Treated With Nivolumab Plus Ipilimumab

被引：0
|
作者：
Remolina-Bonilla, Yuly A. [1 ]
Jimenez-Franco, Brenda [1 ]
Lam, Elaine T. [2 ]
Bourlon, Maria T. [3 ]
机构：
[1] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico
[2] Univ Colorado, Dept Med, Div Med Oncol, Anschutz Med Campus, Aurora, CO USA
[3] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Hematol & Med Oncol Dept, Mexico City, DF, Mexico
来源：
ONCOLOGY-NEW YORK | 2020年 / 34卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：171 / 174
页数：4
相关论文
共 50 条
  • [1] Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
    Ikeda, Takashi
    Ishihara, Hiroki
    Nemoto, Yuki
    Tachibana, Hidekazu
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Takagi, Toshio
    Iizuka, Junpei
    Hashimoto, Yasunobu
    Ishida, Hideki
    Kondo, Tsunenori
    Tanabe, Kazunari
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (10) : 735.e9 - 735.e16
  • [2] Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
    Zhou, Shi
    Khanal, Samrat
    Zhang, Haijun
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2019, 15 : 211 - 221
  • [3] Association between immune-related adverse events and survival in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
    Hayase, T.
    Washino, S.
    Shirotake, S.
    Inoue, M.
    Kagawa, M.
    Takeshita, H.
    Miura, Y.
    Hyodo, Y.
    Izumi, K.
    Kawakami, S.
    Saito, K.
    Kageyama, Y.
    Oyama, M.
    Miyagawa, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S1488 - S1489
  • [4] IMMUNE-RELATED ADVERSE EVENTS ASSOCIATED WITH BETTER SURVIVAL OUTCOMES FOR METASTATIC RENAL CELL CARCINOMA TREATED WITH NIVOLUMAB PLUS IPILIMUMAB
    Numakura, Kazuyuki
    Hatakeyama, Shingo
    Sekine, Yuya
    Muto, Yumina
    Kobayashi, Mizuki
    Kashima, Soki
    Yamamoto, Ryohei
    Koizumi, Atsushi
    Nara, Taketoshi
    Saito, Mitsuru
    Narita, Shintaro
    Ohyama, Chikara
    Habuchi, Tomonori
    JOURNAL OF UROLOGY, 2022, 207 (05): : E175 - E175
  • [5] Ipilimumab and nivolumab induced immune-related adverse events in metastatic mucosal melanoma
    Cao, Yenong
    Afzal, Muhammad Zubair
    Shirai, Keisuke
    BMJ CASE REPORTS, 2021, 14 (08)
  • [6] Immune-related adverse events are clinical biomarkers to predict favorable outcomes in advanced renal cell carcinoma treated with nivolumab plus ipilimumab
    Ueda, Kosuke
    Suekane, Shigetaka
    Kurose, Hirofumi
    Ito, Naoki
    Ogasawara, Naoyuki
    Hiroshige, Tasuku
    Chikui, Katsuaki
    Ejima, Kazuhisa
    Uemura, Keiichiro
    Nakiri, Makoto
    Nishihara, Kiyoaki
    Igawa, Tsukasa
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (05) : 479 - 485
  • [7] Experience of immune-related adverse events associated with ipilimumab and nivolumab in a single center.
    Rapoport, Bernardo Leon
    Smit, Teresa
    van Eeden, Ronwyn
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
  • [8] Ipilimumab/nivolumab/pembrolizumabPancreatic atrophy and immune-related adverse events: 31 case reports
    Reactions Weekly, 2019, 1735 (1) : 162 - 162
  • [9] Immune related adverse events associated with ipilimumab and nivolumab
    Rapoport, B.
    Van Eeden, R. I.
    Smit, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] Relation of overall tumor burden with severe immune-related adverse events in nivolumab plus ipilimumab treatment for lung cancer
    Toshiyuki Sumi
    Motoki Sekikawa
    Yuta Nagahisa
    Keigo Matsuura
    Naoki Shijubou
    Koki Kamada
    Hiroki Watanabe
    Yuichi Yamada
    Yusuke Tanaka
    Hirofumi Chiba
    Investigational New Drugs, 2022, 40 : 1315 - 1321
12345